Guanfacine for the treatment of attention deficit hyperactivity disorder in children and adolescents

被引：8

作者：

Rizzo, Renata ^{[1
]}

Martino, Davide ^{[2
,3
]}

机构：

[1] Univ Catania, Neuropsichiatria Infantile, Dipartimento Sci Med & Pediat, I-95123 Catania, Italy

[2] Kings Coll Hosp NHS Fdn Trust, Dept Neurol, London, England

[3] Queen Elizabeth Hosp, Lewisham & Greenwich NHS Trust, London, England

来源：

EXPERT REVIEW OF NEUROTHERAPEUTICS | 2015年 / 15卷 / 04期

关键词：

alpha(2)-adrenoreceptor agonist; attention deficit hyperactivity disorder; guanfacine extended-release; guanfacine immediate-release; treatment; EXTENDED-RELEASE; DEFICIT/HYPERACTIVITY DISORDER; DOUBLE-BLIND; OPEN-LABEL; LONG-TERM; PHASE-I; ADHD; PHARMACOKINETICS; PSYCHOSTIMULANTS; NEUROBIOLOGY;

D O I：

10.1586/14737175.2015.1028370

中图分类号：

R74 [神经病学与精神病学];

学科分类号：

摘要：

Guanfacine is an (2A)-adrenoreceptor agonist currently indicated for the treatment of attention deficit hyperactivity disorder (ADHD). This article reviews the chemistry, pharmacodynamics and pharmacokinetics of guanfacine, as well as the clinical trial literature on guanfacine for the treatment of ADHD in children and adolescents, mainly focusing on the use of guanfacine extended-release (GXR). Six already published prospective randomized controlled trials (RCTs) and one unpublished RCT study were identified for GXR in the treatment of ADHD. All RCTs trials showed superiority over placebo on the primary outcome measure. Guanfacine, especially XR, seems to be an effective and safe treatment option for ADHD in children and adolescents.

引用

页码：347 / 354

页数：8

共 50 条

[31] Guanfacine (Intuniv) for Attention-Deficit/Hyperactivity Disorder
Bernknopf, Allison
AMERICAN FAMILY PHYSICIAN, 2011, 83 (04) : 468 - +
[32] The effect of guanfacine treatment on ocular parameters in pediatric and adolescents patients with attention-deficit/hyperactivity disorder
Torun, Isil Merve
Pinar, Zeynep Vatansever
Ilhan, Seyma
BMC OPHTHALMOLOGY, 2025, 25 (01)
[33] Attention deficit hyperactivity disorder (ADHD) in children and adolescents
Said, Zead
Huzair, Hifzi
Helal, Muhammad Nabeel
Mushtaq, Imran
PROGRESS IN NEUROLOGY AND PSYCHIATRY, 2015, 19 (03) : 16 - 23
[34] Attention Deficit-Hyperactivity Disorder in Children and Adolescents
Feldman, Heidi M.
Reiff, Michael I.
NEW ENGLAND JOURNAL OF MEDICINE, 2014, 370 (09): : 838 - 846
[35] Attention-Deficit/Hyperactivity Disorder in Children and Adolescents
Carbray, Julie A.
JOURNAL OF PSYCHOSOCIAL NURSING AND MENTAL HEALTH SERVICES, 2018, 56 (12) : 7 - 10
[36] Efficacy of Guanfacine Extended Release in Children and Adolescents with Attention-Deficit/Hyperactivity Disorder and Comorbid Oppositional Defiant Disorder
Newcorn, Jeffrey H.
Huss, Michael
Connor, Daniel F.
Hervas, Amaia
Werner-Kiechle, Tamara
Robertson, Brigitte
JOURNAL OF DEVELOPMENTAL AND BEHAVIORAL PEDIATRICS, 2020, 41 (07): : 565 - 570
[37] Amphetamines for attention deficit hyperactivity disorder in children and adolescents
Feldman, Mark E.
PAEDIATRICS & CHILD HEALTH, 2017, 22 (05) : 288 - +
[38] Attention-deficit/hyperactivity disorder in children and adolescents
Dunn, DW
Kronenberger, WG
NEUROLOGIC CLINICS, 2003, 21 (04) : 933 - +
[39] Attention deficit hyperactivity disorder and enuresis in children and adolescents
Zavadenko N.N.
Kolobova N.M.
Suvorinova N.Yu.
Neuroscience and Behavioral Physiology, 2011, 41 (5) : 525 - 531
[40] Guanfacine Extended Release Adjunctive to a Psychostimulant in the Treatment of Comorbid Oppositional Symptoms in Children and Adolescents with Attention-Deficit/Hyperactivity Disorder
Findling, Robert L.
McBurnett, Keith
White, Carla
Youcha, Sharon
JOURNAL OF CHILD AND ADOLESCENT PSYCHOPHARMACOLOGY, 2014, 24 (05) : 245 - 252

← 1 2 3 4 5 →